Xilio Therapeutics (XLO) Expected to Release Earnings on Thursday

Xilio Therapeutics (NASDAQ:XLO) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.59) per share and revenue of $12.72 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 9:30 AM ET.

Xilio Therapeutics (NASDAQ:XLO) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.08. Xilio Therapeutics had a negative net margin of 58.52% and a negative return on equity of 151.42%. The company had revenue of $12.65 million for the quarter, compared to the consensus estimate of $8.52 million.

Xilio Therapeutics Stock Performance

Shares of NASDAQ:XLO opened at $9.18 on Wednesday. The company has a 50-day simple moving average of $8.84 and a 200-day simple moving average of $8.36. Xilio Therapeutics has a one year low of $6.47 and a one year high of $12.74. The stock has a market capitalization of $60.40 million, a price-to-earnings ratio of -2.58 and a beta of -0.14.

Analysts Set New Price Targets

A number of research firms recently issued reports on XLO. Wall Street Zen lowered Xilio Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings downgraded Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Xilio Therapeutics

Institutional investors have recently bought and sold shares of the company. Bain Capital Life Sciences Investors LLC lifted its stake in shares of Xilio Therapeutics by 61.4% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 7,372,686 shares of the company’s stock worth $4,720,000 after acquiring an additional 2,805,869 shares during the period. Ghisallo Capital Management LLC purchased a new stake in shares of Xilio Therapeutics in the fourth quarter valued at about $713,000. Renaissance Technologies LLC increased its stake in shares of Xilio Therapeutics by 68.3% during the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock worth $220,000 after acquiring an additional 139,716 shares during the period. Squarepoint Ops LLC increased its stake in shares of Xilio Therapeutics by 39.6% during the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after acquiring an additional 93,338 shares during the period. Finally, State Street Corp raised its holdings in Xilio Therapeutics by 13.7% during the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock worth $119,000 after purchasing an additional 22,500 shares in the last quarter. 54.29% of the stock is owned by institutional investors and hedge funds.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.